{
    "pubmed_id": 34107529,
    "study_identifier": "PMID34107529_study-01",
    "study_name": "Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans",
    "publication_title": "Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans",
    "study_objective": "To evaluate the immunogenicity of Ad26.COV2.S vaccine in humans against SARS-CoV-2 variants .",
    "study_description": "The Ad26.COV2.S vaccine1-3 has demonstrated clinical efficacy against symptomatic COVID-19, including against the B.1.351 variant that is partially resistant to neutralizing antibodies1. However, the immunogenicity of this vaccine in humans against SARS-CoV-2 variants of concern remains unclear. Here we report humoral and cellular immune responses from 20 Ad26.COV2.S vaccinated individuals from the COV1001 phase I-IIa clinical trial2 against the original SARS-CoV-2 strain WA1/2020 as well as against the B.1.1.7, CAL.20C, P.1 and B.1.351 variants of concern. Ad26.COV2.S induced median pseudovirus neutralizing antibody titres that were 5.0-fold and 3.3-fold lower against the B.1.351 and P.1 variants, respectively, as compared with WA1/2020 on day 71 after vaccination. Median binding antibody titres were 2.9-fold and 2.7-fold lower against the B.1.351 and P.1 variants, respectively, as compared with WA1/2020. Antibody-dependent cellular phagocytosis, complement deposition and natural killer cell activation responses were largely preserved against the B.1.351 variant. CD8 and CD4 T cell responses, including central and effector memory responses, were comparable among the WA1/2020, B.1.1.7, B.1.351, P.1 and CAL.20C variants. These data show that neutralizing antibody responses induced by Ad26.COV2.S were reduced against the B.1.351 and P.1 variants, but functional non-neutralizing antibody responses and T cell responses were largely preserved against SARS-CoV-2 variants. These findings have implications for vaccine protection against SARS-CoV-2 variants of concern.",
    "primary_institution_name": "Harvard University",
    "study_personnel": [
        {
            "personnel_id": "PMID34107529_personnel-01",
            "honorific": "",
            "last_name": "Barouch",
            "first_name": "Dan",
            "suffixes": "",
            "organization": "Harvard University",
            "orchid_id": "",
            "email": "dbarouch@bidmc.harvard.edu",
            "seronet_title_in_study": "SeroNet Principal Investigator",
            "role_in_study": "Principal Investigator",
            "site_name": "Harvard University"
        }
    ],
    "study_file": [
        {
            "study_file_name": "PMID-34107529_Fig.1_01-05-22.xlsx",
            "study_file_description": "Study Data",
            "study_file_type": "Study Data"
        },
        {
            "study_file_name": "PMID-34107529_Fig.2_01-05-22.xlsx",
            "study_file_description": "Study Data",
            "study_file_type": "Study Data"
        },
        {
            "study_file_name": "PMID-34107529_Fig.3_01-05-22.xlsx",
            "study_file_description": "Study Data",
            "study_file_type": "Study Data"
        },
        {
            "study_file_name": "PMID-34107529_Fig.4A Non-Spike_01-05-22.pdf",
            "study_file_description": "Study Data",
            "study_file_type": "Study Data"
        },
        {
            "study_file_name": "PMID-34107529_Fig.4A Spike_01-05-22.pdf",
            "study_file_description": "Study Data",
            "study_file_type": "Study Data"
        },
        {
            "study_file_name": "PMID-34107529_Fig.4B CD4_01-05-22.pdf",
            "study_file_description": "Study Data",
            "study_file_type": "Study Data"
        },
        {
            "study_file_name": "PMID-34107529_Fig.4B CD8_01-05-22.pdf",
            "study_file_description": "Study Data",
            "study_file_type": "Study Data"
        },
        {
            "study_file_name": "41586_2021_3681_MOESM1_ESM.pdf",
            "study_file_description": "Study Summary Description",
            "study_file_type": "Study Summary Description"
        },
        {
            "study_file_name": "PMID34107529_v1.2.3.xlsm",
            "study_file_description": "Completed curation of the study into SeroNet Registry Template which includes SeroNet Study Descriptors.",
            "study_file_type": "Study Summary Description"
        }
    ],
    "study_link": [],
    "research_focus": "Vaccine Response",
    "study_type": "Clinical Research",
    "keyword": [
        "Ad26COVS1",
        "Adolescent",
        "Adult Antibodies Neutralizing immunology",
        "Antibodies Viral immunology",
        "COVID-19 immunology",
        "COVID-19 prevention control",
        "COVID-19 virology",
        "COVID-19 Vaccines administration & dosage",
        "COVID-19 Vaccines immunology",
        "Humans",
        "Immunity Cellular",
        "Immunity Humoral",
        "Middle Aged",
        "SARS-CoV-2 genetics",
        "SARS-CoV-2 immunology",
        "Spike Glycoprotein",
        "Coronavirus chemistry",
        "Spike Glycoprotein Coronavirus genetics",
        "Spike Glycoprotein Coronavirus immunology",
        "Young Adult",
        "Electrochemiluminescence Immunoassay (eCLIA)",
        "antibody-dependent cellular phagocytosis (ADCP) assay",
        "antibody-mediated neutrophil phagocytosis (ADNP) assay",
        "antibody-dependent complement deposition (ADCD) assay",
        "antibody-dependent natural killer cell activation (ADNKA)"
    ],
    "clinical_study_design": "Randomized Controlled Trial",
    "in_silico_model_type": "",
    "protocol": {
        "protocol_id": "PMID34107529_protocol-01",
        "protocol_file_name": "PMID34107529_protocol-01.txt",
        "protocol_name": "PMID34107529_protocol-01",
        "protocol_description": "Study Protocol",
        "protocol_type": "Study Protocol"
    },
    "reported_health_condition": [
        "Covid-19"
    ],
    "sars_cov_2_vaccine_type": [
        "Johnson & Johnson"
    ],
    "clinical_outcome_measure": "Humoral and cellular immune responses from 20 Ad26.COV2.S vaccinated individuals",
    "enrollment_start_date": "2020-07-29",
    "enrollment_end_date": "2020-08-07",
    "number_of_study_subjects": 25,
    "age_unit": "Years",
    "minimum_age": 18,
    "maximum_age": 55,
    "study_human_cohort": [
        {
            "arm_id": "PMID34107529_human_subject-01",
            "arm_name": "Group 1 individuals from Cohort 1b",
            "study_population_description": "Group 1 individuals received 5 \u00d7 10^10 viral particles of Ad26.COV2.S on days 1 and 57 (low-dose\u2013low-dose, N= 5)",
            "arm_type": "Experimental Arm",
            "ethnicity": [
                "Not Specified"
            ],
            "race": [
                "Not Specified"
            ],
            "race_specify": [],
            "description": "",
            "sex_at_birth": [
                "Not specified"
            ],
            "age_event": "Not Specified",
            "subject_phenotype": "",
            "assessment_name": [],
            "study_location": [
                "US: Massachusetts"
            ],
            "measured_behavioral_or_pyschological_factor": [],
            "measured_social_factor": [],
            "sars_cov_2_symptoms": [],
            "assessment_clinical_and_demographic_data_provenance": [],
            "assessment_demographic_data_types_collected": [],
            "sars_cov_2_history": [
                "Vaccinated"
            ],
            "sars_cov_2_vaccine_type": [
                "Johnson & Johnson COVID-19 vaccine; VO:0005159"
            ],
            "covid_19_disease_severity": [],
            "post_covid_19_symptoms": [],
            "covid_19_complications": []
        },
        {
            "arm_id": "PMID34107529_human_subject-02",
            "arm_name": "Group 2 individuals from Cohort 1b",
            "study_population_description": "Group 2 individuals received 5 \u00d7 10^10 viral particles of Ad26.COV2.S on day 1 and placebo on day 57 as a single-shot vaccine (low-dose\u2013placebo, N= 5)",
            "arm_type": "Experimental Arm",
            "ethnicity": [
                "Not Specified"
            ],
            "race": [
                "Not Specified"
            ],
            "race_specify": [],
            "description": "",
            "sex_at_birth": [
                "Not specified"
            ],
            "age_event": "Not Specified",
            "subject_phenotype": "",
            "assessment_name": [],
            "study_location": [
                "US: Massachusetts"
            ],
            "measured_behavioral_or_pyschological_factor": [],
            "measured_social_factor": [],
            "sars_cov_2_symptoms": [],
            "assessment_clinical_and_demographic_data_provenance": [],
            "assessment_demographic_data_types_collected": [],
            "sars_cov_2_history": [
                "Vaccinated"
            ],
            "sars_cov_2_vaccine_type": [
                "Johnson & Johnson COVID-19 vaccine; VO:0005159"
            ],
            "covid_19_disease_severity": [],
            "post_covid_19_symptoms": [],
            "covid_19_complications": []
        },
        {
            "arm_id": "PMID34107529_human_subject-03",
            "arm_name": "Group 3 individuals from Cohort 1b",
            "study_population_description": "Group 3 individuals received 1 \u00d7 10^11 viral particles of Ad26.COV2.S on days 1 and 57 (high-dose\u2013high-dose, N= 5)",
            "arm_type": "Experimental Arm",
            "ethnicity": [
                "Not Specified"
            ],
            "race": [
                "Not Specified"
            ],
            "race_specify": [],
            "description": "",
            "sex_at_birth": [
                "Not specified"
            ],
            "age_event": "Not Specified",
            "subject_phenotype": "",
            "assessment_name": [],
            "study_location": [
                "US: Massachusetts"
            ],
            "measured_behavioral_or_pyschological_factor": [],
            "measured_social_factor": [],
            "sars_cov_2_symptoms": [],
            "assessment_clinical_and_demographic_data_provenance": [],
            "assessment_demographic_data_types_collected": [],
            "sars_cov_2_history": [
                "Vaccinated"
            ],
            "sars_cov_2_vaccine_type": [
                "Johnson & Johnson COVID-19 vaccine; VO:0005159"
            ],
            "covid_19_disease_severity": [],
            "post_covid_19_symptoms": [],
            "covid_19_complications": []
        },
        {
            "arm_id": "PMID34107529_human_subject-04",
            "arm_name": "Group 4 individuals from Cohort 1b",
            "study_population_description": "Group 4 individuals received 1 \u00d7 10^11 viral particles of Ad26.COV2.S on day 1 and placebo on day 57 as a single-shot vaccine (high-dose\u2013placebo, N= 5)",
            "arm_type": "Experimental Arm",
            "ethnicity": [
                "Not Specified"
            ],
            "race": [
                "Not Specified"
            ],
            "race_specify": [],
            "description": "",
            "sex_at_birth": [
                "Not specified"
            ],
            "age_event": "Not Specified",
            "subject_phenotype": "",
            "assessment_name": [],
            "study_location": [
                "US: Massachusetts"
            ],
            "measured_behavioral_or_pyschological_factor": [],
            "measured_social_factor": [],
            "sars_cov_2_symptoms": [],
            "assessment_clinical_and_demographic_data_provenance": [],
            "assessment_demographic_data_types_collected": [],
            "sars_cov_2_history": [
                "Vaccinated"
            ],
            "sars_cov_2_vaccine_type": [
                "Johnson & Johnson COVID-19 vaccine; VO:0005159"
            ],
            "covid_19_disease_severity": [],
            "post_covid_19_symptoms": [],
            "covid_19_complications": []
        },
        {
            "arm_id": "PMID34107529_human_subject-05",
            "arm_name": "Group 5 individuals from Cohort 1b",
            "study_population_description": "Group 5 individuals received, placebo on days 1 and 57 (placebo\u2013placebo, N= 5).",
            "arm_type": "Placebo Comparator Arm",
            "ethnicity": [
                "Not Specified"
            ],
            "race": [
                "Not Specified"
            ],
            "race_specify": [],
            "description": "",
            "sex_at_birth": [
                "Not specified"
            ],
            "age_event": "Not Specified",
            "subject_phenotype": "",
            "assessment_name": [],
            "study_location": [
                "US: Massachusetts"
            ],
            "measured_behavioral_or_pyschological_factor": [],
            "measured_social_factor": [],
            "sars_cov_2_symptoms": [],
            "assessment_clinical_and_demographic_data_provenance": [],
            "assessment_demographic_data_types_collected": [],
            "sars_cov_2_history": [
                "Not vaccinated"
            ],
            "sars_cov_2_vaccine_type": [],
            "covid_19_disease_severity": [],
            "post_covid_19_symptoms": [],
            "covid_19_complications": []
        }
    ],
    "study_model_cohort": [],
    "planned_visit": [
        {
            "visit_id": "PMID34107529_visit-01",
            "visit_name": "Group 1, 2, 3, 4 individuals received vaccine and Group 5 individuals received placebo on day 1",
            "visit_order_number": 1,
            "visit_min_start_day": 1,
            "visit_max_start_day": "",
            "visit_start_rule": ""
        },
        {
            "visit_id": "PMID34107529_visit-02",
            "visit_name": "Group 1, 3 received vaccine. Group 2, 4, 5 received placebo. CD8 T cell response measured in vaccine and placebo groups",
            "visit_order_number": 2,
            "visit_min_start_day": 57,
            "visit_max_start_day": "",
            "visit_start_rule": ""
        },
        {
            "visit_id": "PMID34107529_visit-03",
            "visit_name": "TCR\u03b2 sequencing was performed at day 63 on vaccine and placebo received individuals",
            "visit_order_number": 4,
            "visit_min_start_day": 63,
            "visit_max_start_day": "",
            "visit_start_rule": ""
        },
        {
            "visit_id": "PMID34107529_visit-04",
            "visit_name": "pseudovirus neutralizing antibody titers were measured on day 71 between vaccine and placebo received groups",
            "visit_order_number": 5,
            "visit_min_start_day": 71,
            "visit_max_start_day": "",
            "visit_start_rule": ""
        },
        {
            "visit_id": "PMID34107529_visit-05",
            "visit_name": "CD8 T cell response were measured in vaccine and placebo received groups on day 85",
            "visit_order_number": 6,
            "visit_min_start_day": 85,
            "visit_max_start_day": "",
            "visit_start_rule": ""
        }
    ],
    "experiment": [
        {
            "arm_id": [
                "PMID34107529_human_subject-01",
                "PMID34107529_human_subject-02",
                "PMID34107529_human_subject-03",
                "PMID34107529_human_subject-04",
                "PMID34107529_human_subject-05"
            ],
            "associated_first_planned_visit_id": [
                "PMID34107529_visit-01",
                "PMID34107529_visit-02",
                "PMID34107529_visit-03",
                "PMID34107529_visit-04"
            ],
            "assay_type": "Pseudovirus Neutralization Assay",
            "experiment_name": "Pseudovirus-based neutralization assay",
            "experiment_results_file_name": "na",
            "biospecimen_type": [
                "Plasma",
                "Serum"
            ],
            "biospecimen_collection_point": [
                "Post-vaccination"
            ],
            "sars_cov_2_antigen": [
                "n/a"
            ],
            "assay_use": "",
            "manufacture": "",
            "catalog_number": "",
            "virus_target": [
                "SARS-CoV-2 WA1/2020 (D614 variant)",
                "SARS-CoV-2 Alpha; B.1.1.7",
                "SARS-CoV-2 Gamma; P.1",
                "SARS-CoV-2 Beta; B.1.351"
            ],
            "antibody_isotype": [
                "Other"
            ],
            "reporting_units": "",
            "assay_reporting_format": "Quantitative"
        },
        {
            "arm_id": [
                "PMID34107529_human_subject-01",
                "PMID34107529_human_subject-02",
                "PMID34107529_human_subject-03",
                "PMID34107529_human_subject-04",
                "PMID34107529_human_subject-05"
            ],
            "associated_first_planned_visit_id": [
                "PMID34107529_visit-01",
                "PMID34107529_visit-02",
                "PMID34107529_visit-03",
                "PMID34107529_visit-04"
            ],
            "assay_type": "Neutralizing Antibody Titer Assay",
            "experiment_name": "Live virus neutralization assay",
            "experiment_results_file_name": "na",
            "biospecimen_type": [
                "Serum"
            ],
            "biospecimen_collection_point": [
                "Post-vaccination"
            ],
            "sars_cov_2_antigen": [
                "n/a"
            ],
            "assay_use": "",
            "manufacture": "",
            "catalog_number": "",
            "virus_target": [
                "SARS-CoV-2 WA1/2020 (D614 variant)",
                "SARS-CoV-2 Alpha; B.1.1.7",
                "SARS-CoV-2 Gamma; P.1",
                "SARS-CoV-2 Beta; B.1.351"
            ],
            "antibody_isotype": [
                "Other"
            ],
            "reporting_units": "",
            "assay_reporting_format": "Quantitative"
        },
        {
            "arm_id": [
                "PMID34107529_human_subject-01",
                "PMID34107529_human_subject-02",
                "PMID34107529_human_subject-03",
                "PMID34107529_human_subject-04",
                "PMID34107529_human_subject-05"
            ],
            "associated_first_planned_visit_id": [
                "PMID34107529_visit-01",
                "PMID34107529_visit-02",
                "PMID34107529_visit-03",
                "PMID34107529_visit-04"
            ],
            "assay_type": "ELISA",
            "experiment_name": "ELISA",
            "experiment_results_file_name": "na",
            "biospecimen_type": [
                "Serum"
            ],
            "biospecimen_collection_point": [
                "Post-vaccination"
            ],
            "sars_cov_2_antigen": [
                "Receptor Binding Domain (RBD)"
            ],
            "assay_use": "",
            "manufacture": "",
            "catalog_number": "",
            "virus_target": [
                "SARS-CoV-2 WA1/2020 (D614 variant)",
                "SARS-CoV-2 Alpha; B.1.1.7",
                "SARS-CoV-2 Gamma; P.1",
                "SARS-CoV-2 Beta; B.1.351"
            ],
            "antibody_isotype": [
                "IgG"
            ],
            "reporting_units": "",
            "assay_reporting_format": ""
        },
        {
            "arm_id": [
                "PMID34107529_human_subject-01",
                "PMID34107529_human_subject-02",
                "PMID34107529_human_subject-03",
                "PMID34107529_human_subject-04",
                "PMID34107529_human_subject-05"
            ],
            "associated_first_planned_visit_id": [
                "PMID34107529_visit-01",
                "PMID34107529_visit-02",
                "PMID34107529_visit-03",
                "PMID34107529_visit-04"
            ],
            "assay_type": "Chemiluminescent Assay",
            "experiment_name": "electrochemiluminescence assay (ECLA)",
            "experiment_results_file_name": "na",
            "biospecimen_type": [
                "Serum"
            ],
            "biospecimen_collection_point": [
                "Post-vaccination"
            ],
            "sars_cov_2_antigen": [
                "Full Length Spike Trimer I Receptor Binding Domain (RBD)"
            ],
            "assay_use": "",
            "manufacture": "",
            "catalog_number": "",
            "virus_target": [
                "SARS-CoV-2 WA1/2020 (D614 variant)",
                "SARS-CoV-2 Alpha; B.1.1.7",
                "SARS-CoV-2 Gamma; P.1",
                "SARS-CoV-2 Beta; B.1.351"
            ],
            "antibody_isotype": [
                "IgG"
            ],
            "reporting_units": "",
            "assay_reporting_format": ""
        },
        {
            "arm_id": [
                "PMID34107529_human_subject-01",
                "PMID34107529_human_subject-02",
                "PMID34107529_human_subject-03",
                "PMID34107529_human_subject-04",
                "PMID34107529_human_subject-05"
            ],
            "associated_first_planned_visit_id": [
                "PMID34107529_visit-01",
                "PMID34107529_visit-02",
                "PMID34107529_visit-03",
                "PMID34107529_visit-04"
            ],
            "assay_type": "Cell Mediated Immunoassay",
            "experiment_name": "ADCP, ADNP, ADCD and ADNKA",
            "experiment_results_file_name": "na",
            "biospecimen_type": [
                "Serum"
            ],
            "biospecimen_collection_point": [
                "Post-vaccination"
            ],
            "sars_cov_2_antigen": [
                "Receptor Binding Domain (RBD)"
            ],
            "assay_use": "",
            "manufacture": "",
            "catalog_number": "",
            "virus_target": [
                "SARS-CoV-2 WA1/2020 (D614 variant)",
                "SARS-CoV-2 Alpha; B.1.1.7",
                "SARS-CoV-2 Gamma; P.1",
                "SARS-CoV-2 Beta; B.1.351"
            ],
            "antibody_isotype": [
                "IgG I IgA I IgM"
            ],
            "reporting_units": "",
            "assay_reporting_format": "Quantitative"
        },
        {
            "arm_id": [
                "PMID34107529_human_subject-01",
                "PMID34107529_human_subject-02",
                "PMID34107529_human_subject-03",
                "PMID34107529_human_subject-04",
                "PMID34107529_human_subject-05"
            ],
            "associated_first_planned_visit_id": [
                "PMID34107529_visit-01",
                "PMID34107529_visit-02",
                "PMID34107529_visit-03",
                "PMID34107529_visit-04",
                "PMID34107529_visit-05"
            ],
            "assay_type": "ELISPOT",
            "experiment_name": "ELISPOT",
            "experiment_results_file_name": "na",
            "biospecimen_type": [
                "Peripheral Blood Mononuclear Cell (PBMC)"
            ],
            "biospecimen_collection_point": [
                "Post-vaccination"
            ],
            "sars_cov_2_antigen": [
                "Other"
            ],
            "assay_use": "",
            "manufacture": "",
            "catalog_number": "",
            "virus_target": [
                "SARS-CoV-2 WA1/2020 (D614 variant)",
                "SARS-CoV-2 Alpha; B.1.1.7",
                "SARS-CoV-2 Gamma; P.1",
                "SARS-CoV-2 Beta; B.1.351"
            ],
            "antibody_isotype": [
                "Other"
            ],
            "reporting_units": "",
            "assay_reporting_format": "Quantitative"
        },
        {
            "arm_id": [
                "PMID34107529_human_subject-01",
                "PMID34107529_human_subject-02",
                "PMID34107529_human_subject-03",
                "PMID34107529_human_subject-04",
                "PMID34107529_human_subject-05"
            ],
            "associated_first_planned_visit_id": [
                "PMID34107529_visit-01",
                "PMID34107529_visit-02",
                "PMID34107529_visit-03",
                "PMID34107529_visit-04",
                "PMID34107529_visit-05"
            ],
            "assay_type": "Flow Cytometry",
            "experiment_name": "ICS assay",
            "experiment_results_file_name": "na",
            "biospecimen_type": [
                "Peripheral Blood Mononuclear Cell (PBMC)"
            ],
            "biospecimen_collection_point": [
                "Post-vaccination"
            ],
            "sars_cov_2_antigen": [],
            "assay_use": "",
            "manufacture": "",
            "catalog_number": "",
            "virus_target": [
                "SARS-COV-2 WA1/2020 I B.1.351 I B.1.1.7 I P.1 I CAL.20C"
            ],
            "antibody_isotype": [
                "Other"
            ],
            "reporting_units": "",
            "assay_reporting_format": "Quantitative"
        },
        {
            "arm_id": [
                "PMID34107529_human_subject-01",
                "PMID34107529_human_subject-02",
                "PMID34107529_human_subject-03",
                "PMID34107529_human_subject-04",
                "PMID34107529_human_subject-05"
            ],
            "associated_first_planned_visit_id": [
                "PMID34107529_visit-01",
                "PMID34107529_visit-02",
                "PMID34107529_visit-03",
                "PMID34107529_visit-04"
            ],
            "assay_type": "T cell receptor repertoire sequencing assay",
            "experiment_name": "T cell receptor variable beta chain sequencing",
            "experiment_results_file_name": "na",
            "biospecimen_type": [
                "Plasma"
            ],
            "biospecimen_collection_point": [
                "Post-vaccination"
            ],
            "sars_cov_2_antigen": [],
            "assay_use": "",
            "manufacture": "",
            "catalog_number": "",
            "virus_target": [
                "SARS-CoV-2 WA1/2020 (D614 variant)",
                "SARS-CoV-2 Alpha; B.1.1.7",
                "SARS-CoV-2 Gamma; P.1",
                "SARS-CoV-2 Beta; B.1.351"
            ],
            "antibody_isotype": [
                "Other"
            ],
            "reporting_units": "",
            "assay_reporting_format": "Quantitative"
        }
    ],
    "geriatric_subjects": "No",
    "pediatric_subjects": "No",
    "pregnant_subjects": "Not Specified",
    "sars_cov_2_antibodies_measured": "Not Specified",
    "survey_instrument_shared": "Not Specified",
    "who_disease_severity_scale_used": "Not Specified",
    "inclusion_exclusion": [
        {
            "inclusion_exculusion_id": "PMID34107529_inexcl-01",
            "inclusion_criterion": "Geriatric subjects",
            "inclusion_criterion_category": "exclusion"
        },
        {
            "inclusion_exculusion_id": "PMID34107529_inexcl-02",
            "inclusion_criterion": "Pediatric subjects",
            "inclusion_criterion_category": "exclusion"
        },
        {
            "inclusion_exculusion_id": "PMID34107529_inexcl-03",
            "inclusion_criterion": "Vaccine receipents",
            "inclusion_criterion_category": "inclusion"
        }
    ]
}
